Understanding and Treating Leukemia

Leukemia is a cancer of the blood and bone marrow — where blood cells are made. Unlike solid tumours (such as breast, lung, or colon cancers), leukaemia does not form a discrete mass. Instead, abnormal leukaemic cells multiply in the bone marrow, crowding out normal blood cell production and circulating in the bloodstream. This disrupts the body's ability to produce functional red blood cells, platelets, and white blood cells, leading to anaemia, bleeding, and infection susceptibility. There are many distinct types of leukaemia — acute and chronic, myeloid and lymphoid — each with its own biology and treatment pathway.

The four major categories are: Acute Myeloid Leukaemia (AML) — the most common acute adult leukaemia, arising from myeloid precursors; Acute Lymphoblastic Leukaemia (ALL) — the most common childhood cancer, arising from lymphoid precursors; Chronic Myeloid Leukaemia (CML) — defined by BCR-ABL1 and managed with TKI therapy; and Chronic Lymphocytic Leukaemia (CLL) — the most common adult chronic leukaemia, increasingly treated with BTK and BCL-2 inhibitors. Many rarer subtypes exist within and alongside these four major categories.

Acute leukaemias (AML and ALL) arise from immature blast cells that proliferate rapidly and accumulate in the bone marrow. They progress over days to weeks and require immediate, intensive treatment. Chronic leukaemias (CML and CLL) arise from more mature cells and evolve slowly — often over months to years. Many patients with chronic leukaemia are asymptomatic at diagnosis, found on a routine blood count. Chronic leukaemias allow a more measured diagnostic and treatment approach, and many are now managed with long-term oral targeted therapies.

Leukaemia diagnosis requires a bone marrow aspirate and trephine biopsy, immunophenotyping by flow cytometry, cytogenetic analysis (karyotype and FISH), and molecular studies (RT-PCR for fusion genes, NGS mutation panel). The combination of these tests establishes the leukaemia subtype, risk category, and targeted therapy eligibility. A full blood count and peripheral blood film are usually the first investigations that raise suspicion, but bone marrow examination is essential to confirm the diagnosis.

Some leukaemia subtypes are highly curable with modern treatment: childhood ALL (particularly standard-risk B-ALL) and APL (with ATRA + arsenic trioxide) achieve durable long-term remissions in the majority of patients. CML, while rarely cured by oral TKI therapy, can achieve treatment-free remission — effectively functioning like a cure — in selected patients. AML and adult ALL remain challenging, with a significant proportion of patients relapsing; allogeneic stem cell transplantation offers a potential cure in eligible high-risk patients. Prognosis is highly individual and depends on subtype, molecular features, age, and treatment access.

CAR-T (Chimeric Antigen Receptor T-cell) therapy involves genetically engineering a patient's own T cells to recognise and destroy leukaemia cells. For leukaemia, approved CAR-T products target the CD19 antigen on B-ALL cells — tisagenlecleucel (Kymriah) is approved for children and young adults with relapsed or refractory B-ALL. CAR-T research in AML and CLL is active, targeting antigens such as CD123, CLL-1, and CD33. CancerFax supports patients in understanding eligibility, navigating the CAR-T manufacturing process, and accessing programmes at specialist centres in India and internationally.

Molecular testing is central to modern leukaemia management. Specific mutations and chromosomal abnormalities — BCR-ABL1, FLT3-ITD, NPM1, IDH1/2, TP53, del(17p), KMT2A rearrangements — determine risk stratification, targeted therapy eligibility, and treatment protocol selection. They also serve as MRD monitoring targets, tracking treatment response at a cellular level beyond what standard blood counts can detect. Comprehensive molecular profiling at diagnosis is now the standard of care at specialist leukaemia centres.

Yes — CancerFax has specific expertise in helping leukaemia patients access advanced treatment programmes internationally. This includes arranging second opinion consultations with haematologists at specialist centres in India, China, and globally; coordinating access to CAR-T cell therapy, clinical trials, and novel targeted agents; organising allogeneic transplant evaluations and logistics; and providing structured medical record review and case summarisation to prepare for specialist consultations. For patients whose treatment options are limited locally, international access can meaningfully expand what is available.

Yes — CancerFax provides comprehensive support for patients across all leukaemia subtypes at every stage of the disease journey. Our services include structured medical record review and molecular profiling assessment, second opinion coordination with dedicated leukaemia specialists, navigation of CAR-T and immunotherapy access programmes, clinical trial matching for patients with relapsed or refractory disease, and logistics support for cross-border treatment in India, China, and internationally. Whether you are newly diagnosed, facing relapse, or seeking access to therapies not available locally, CancerFax can help map your options. Share your reports or contact our team to get started.